BACKGROUND: The etiology of steroid-resistant nephrotic syndrome, which manifests as FSGS, is not completely understood. Aberrant glycosylation is an often underestimated factor for pathologic processes, and structural changes in the glomerular endothelial glycocalyx have been correlated with models of nephrotic syndrome. Glycans are frequently capped by sialic acid (Sia), and sialylation's crucial role for kidney function is well known. Human podocytes are highly sialylated; however, sialylation's role in podocyte homeostasis remains unclear. METHODS: We generated a podocyte-specific sialylation-deficient mouse model (PCmas-/- ) by targeting CMP-Sia synthetase, and used histologic and ultrastructural analysis to decipher the phenotype. We applied CRISPR/Cas9 technology to generate immortalized sialylation-deficient podocytes (asialo-podocytes) for functional studies. RESULTS: Progressive loss of sialylation in PCmas-/- mice resulted in onset of proteinuria around postnatal day 28, accompanied by foot process effacement and loss of slit diaphragms. Podocyte injury led to severe glomerular defects, including expanded capillary lumen, mesangial hypercellularity, synechiae formation, and podocyte loss. In vivo, loss of sialylation resulted in mislocalization of slit diaphragm components, whereas podocalyxin localization was preserved. In vitro, asialo-podocytes were viable, able to proliferate and differentiate, but showed impaired adhesion to collagen IV. CONCLUSIONS: Loss of cell-surface sialylation in mice resulted in disturbance of podocyte homeostasis and FSGS development. Impaired podocyte adhesion to the glomerular basement membrane most likely contributed to disease development. Our data support the notion that loss of sialylation might be part of the complex process causing FSGS. Sialylation, such as through a Sia supplementation therapy, might provide a new therapeutic strategy to cure or delay FSGS and potentially other glomerulopathies.
BACKGROUND: The etiology of steroid-resistant nephrotic syndrome, which manifests as FSGS, is not completely understood. Aberrant glycosylation is an often underestimated factor for pathologic processes, and structural changes in the glomerular endothelial glycocalyx have been correlated with models of nephrotic syndrome. Glycans are frequently capped by sialic acid (Sia), and sialylation's crucial role for kidney function is well known. Human podocytes are highly sialylated; however, sialylation's role in podocyte homeostasis remains unclear. METHODS: We generated a podocyte-specific sialylation-deficient mouse model (PCmas-/- ) by targeting CMP-Sia synthetase, and used histologic and ultrastructural analysis to decipher the phenotype. We applied CRISPR/Cas9 technology to generate immortalized sialylation-deficient podocytes (asialo-podocytes) for functional studies. RESULTS: Progressive loss of sialylation in PCmas-/- mice resulted in onset of proteinuria around postnatal day 28, accompanied by foot process effacement and loss of slit diaphragms. Podocyte injury led to severe glomerular defects, including expanded capillary lumen, mesangial hypercellularity, synechiae formation, and podocyte loss. In vivo, loss of sialylation resulted in mislocalization of slit diaphragm components, whereas podocalyxin localization was preserved. In vitro, asialo-podocytes were viable, able to proliferate and differentiate, but showed impaired adhesion to collagen IV. CONCLUSIONS: Loss of cell-surface sialylation in mice resulted in disturbance of podocyte homeostasis and FSGS development. Impaired podocyte adhesion to the glomerular basement membrane most likely contributed to disease development. Our data support the notion that loss of sialylation might be part of the complex process causing FSGS. Sialylation, such as through a Sia supplementation therapy, might provide a new therapeutic strategy to cure or delay FSGS and potentially other glomerulopathies.
Authors: S Doublier; V Ruotsalainen; G Salvidio; E Lupia; L Biancone; P G Conaldi; P Reponen; K Tryggvason; G Camussi Journal: Am J Pathol Date: 2001-05 Impact factor: 4.307
Authors: Sangeeta R Hingorani; Laura S Finn; Jolanta Kowalewska; Ruth A McDonald; Allison A Eddy Journal: Pediatr Nephrol Date: 2004-01-28 Impact factor: 3.714
Authors: Nayia Nicolaou; Coert Margadant; Sietske H Kevelam; Marc R Lilien; Michiel J S Oosterveld; Maaike Kreft; Albertien M van Eerde; Rolph Pfundt; Paulien A Terhal; Bert van der Zwaag; Peter G J Nikkels; Norman Sachs; Roel Goldschmeding; Nine V A M Knoers; Kirsten Y Renkema; Arnoud Sonnenberg Journal: J Clin Invest Date: 2012-11-01 Impact factor: 14.808
Authors: Brian R Stotter; Brianna E Talbot; Diane E Capen; Nadine Artelt; Junwei Zeng; Yasuyuki Matsumoto; Nicole Endlich; Richard D Cummings; Johannes S Schlondorff Journal: Am J Physiol Renal Physiol Date: 2020-01-06
Authors: Annika Möller-Kerutt; Juan E Rodriguez-Gatica; Karin Wacker; Rohan Bhatia; Jan-Peter Siebrasse; Nanda Boon; Veerle Van Marck; Peter Boor; Ulrich Kubitscheck; Jan Wijnholds; Hermann Pavenstädt; Thomas Weide Journal: J Am Soc Nephrol Date: 2021-03-09 Impact factor: 10.121